Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

AKI Associated with Acute Pancreatitis.

Nassar TI, Qunibi WY.

Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1106-1115. doi: 10.2215/CJN.13191118. Epub 2019 May 22.

PMID:
31118209
2.

Vascular access mortality and hospitalization among hemodialysis patients in Palestine.

Hamadneh SA, Nueirat SA, Qadoomi' J, Shurrab M, Qunibi WY, Hamdan Z.

Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):120-126. doi: 10.4103/1319-2442.225184.

3.

Dyslipidemia in Dialysis Patients.

Qunibi WY.

Semin Dial. 2015 Jul-Aug;28(4):345-53. doi: 10.1111/sdi.12375. Epub 2015 Apr 9. Review.

PMID:
25855389
4.

Treatment of vitamin D deficiency/insufficiency with ergocalciferol is associated with reduced vascular access dysfunction in chronic hemodialysis patients.

Agarwal G, Vasquez K, Penagaluru N, Gelfond J, Qunibi WY.

Hemodial Int. 2015 Oct;19(4):499-508. doi: 10.1111/hdi.12292. Epub 2015 Mar 19.

PMID:
25790374
5.

Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.

Qunibi WY.

J Am Soc Nephrol. 2015 Oct;26(10):2311-3. doi: 10.1681/ASN.2015020135. Epub 2015 Mar 3. No abstract available.

6.

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B.

JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688. Erratum in: JAMA. 2015 Feb 3;313(5):526. Dosage error in text.

PMID:
25402495
7.

Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.

Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT.

Nephrol Dial Transplant. 2014 Apr;29(4):833-42. doi: 10.1093/ndt/gft251. Epub 2013 Aug 20.

PMID:
23963731
8.

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD.

Nephrol Dial Transplant. 2011 May;26(5):1599-607. doi: 10.1093/ndt/gfq613. Epub 2010 Oct 7.

9.

The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.

Qunibi WY.

Arzneimittelforschung. 2010;60(6a):399-412. doi: 10.1055/s-0031-1296304. Review.

PMID:
20648931
10.

Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate?

Qunibi WY, Abdellatif A, Sankar S, Hamdan Z, Lin FY, Ingle J, Cadena A, Gelfond J, Kasinath B.

Clin Nephrol. 2010 Apr;73(4):276-85.

PMID:
20353735
11.

Cardiovascular calcification in nondialyzed patients with chronic kidney disease.

Qunibi WY.

Semin Dial. 2007 Mar-Apr;20(2):134-8. Review.

PMID:
17374087
12.

Does sevelamer have anti-atherosclerotic properties in maintenance hemodialysis patients?

Qunibi WY.

Nat Clin Pract Nephrol. 2005 Nov;1(1):18-9. No abstract available.

PMID:
16932359
13.

The CARE study and cardiovascular calcification.

Qunibi WY.

Manag Care. 2006 Mar;15(3 Suppl):1-5.

15.

Reducing the burden of cardiovascular calcification in patients with chronic kidney disease.

Qunibi WY.

J Am Soc Nephrol. 2005 Nov;16 Suppl 2:S95-102. Review.

16.

Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes.

Qunibi WY, Abouzahr F, Mizani MR, Nolan CR, Arya R, Hunt KJ.

Kidney Int. 2005 Jul;68(1):271-7.

17.
18.
19.

Economic impact of sevelamer in patients with ESRD.

Qunibi WY, Nolan CR.

Kidney Int. 2005 Apr;67(4):1636-7. No abstract available.

20.

Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.

Brezina B, Qunibi WY, Nolan CR.

Kidney Int Suppl. 2004 Sep;(90):S39-45. Review.

PMID:
15296506
21.
22.

Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).

Qunibi WY.

Kidney Int Suppl. 2004 Sep;(90):S8-S12. Review.

PMID:
15296501
23.

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR.

Kidney Int. 2004 May;65(5):1914-26.

24.

Kaposi's sarcoma in Sudanese renal transplant recipients: a report from a single center.

Sabeel AI, Qunibi WY, Alfurayh OA, Al-Meshari K.

J Nephrol. 2003 May-Jun;16(3):412-6.

PMID:
12832743
25.

Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.

Nolan CR, Qunibi WY.

Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Review.

PMID:
12815333
26.

Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.

Qunibi WY, Nolan CA, Ayus JC.

Kidney Int Suppl. 2002 Dec;(82):S73-80. Review.

27.

How should hyperphosphatemia be managed in dialysis patients?

Block G, Uribarri J, Coladonato JA, Fan SL, Cunningham J, Nolan CR, Qunibi WY, Lindberg JS.

Semin Dial. 2002 Sep-Oct;15(5):315-28. Review. No abstract available.

PMID:
12358631
28.

Ownership of dialysis facilities and patients' survival.

Qunibi WY, Riley DJ, Abboud HE.

N Engl J Med. 2000 Apr 6;342(14):1055; author reply 1055-6. No abstract available.

PMID:
10755901
29.

Improving utilization of intravenous immune globulin through concurrent use of an indication form.

Frayha HH, Nuessle SJ, Arishi H, Rayes H, Qunibi WY, Bazarbashi MS.

Eur J Clin Pharmacol. 1997;52(4):255-60.

PMID:
9248761
30.

Impact of hepatitis C virus infection on kidney transplant outcome.

Alfurayh OI, Sobh MA, Chaudry TS, Qunibi WY, Al Meshari K, Ellis M, Ali MA, Taher S.

Saudi J Kidney Dis Transpl. 1995 April-June;6(2):183-9.

31.

Commercial renal transplantation: Clinical and ethical issues.

Qunibi WY.

Ann Saudi Med. 1994 Jan;14(1):1-4. No abstract available.

32.

Vancomycin resistant enterococcus: A case report and review of the literature.

Qadri SH, Qunibi WY, Al-Ballaa SR, Kadhi Y, Burdette JM.

Ann Saudi Med. 1993 May;13(3):289-93. No abstract available.

33.

Kaposi's sarcoma in renal transplant recipients: a report on 26 cases from a single institution.

Qunibi WY, Barri Y, Alfurayh O, Almeshari K, Khan B, Taher S, Sheth K.

Transplant Proc. 1993 Feb;25(1 Pt 2):1402-5. No abstract available.

PMID:
8442155
34.

Factors predictive of post-transplant erythrocytosis.

Qunibi WY, Barri Y, Devol E, al-Furayh O, Sheth K, Taher S.

Kidney Int. 1991 Dec;40(6):1153-9.

35.

Mycobacterial infection after renal transplantation--report of 14 cases and review of the literature.

Qunibi WY, al-Sibai MB, Taher S, Harder EJ, de Vol E, al-Furayh O, Ginn HE.

Q J Med. 1990 Oct;77(282):1039-60. Review.

PMID:
2267281
36.

Mesangio-proliferative glomerulonephritis associated with Kimura's disease.

Qunibi WY, Al-Sibai MB, Akhtar M.

Clin Nephrol. 1988 Aug;30(2):111-4.

PMID:
3180515
37.

Kaposi's sarcoma in cyclosporine-induced gingival hyperplasia.

Qunibi WY, Akhtar M, Ginn E, Smith P.

Am J Kidney Dis. 1988 Apr;11(4):349-52.

PMID:
3281453
38.

Renal autotransplantation for severe sickle cell haematuria.

Qunibi WY.

Lancet. 1988 Jan 30;1(8579):236-7. No abstract available.

PMID:
2893056
39.
40.

Renal papillary necrosis: an update.

Eknoyan G, Qunibi WY, Grissom RT, Tuma SN, Ayus JC.

Medicine (Baltimore). 1982 Mar;61(2):55-73. Review.

PMID:
7038374
41.

Renal transplant ureteric obstruction by periureteric fibrosis.

Qunibi WY, Chavez A, Guerriero WG, Suki WN.

Am J Nephrol. 1982;2(2):91-4. No abstract available.

PMID:
6758583
42.

Toxic nephropathy during continuous rifampin therapy.

Qunibi WY, Godwin J, Eknoyan G.

South Med J. 1980 Jun;73(6):791-2.

PMID:
7394612
43.

Nephrotic syndrome in anti-GBM antibody mediated glomerulonephritis.

Qunibi WY, Taylor K, Knight TF, Senekjian HO, Gy├Ârkey F, Weinman EJ.

South Med J. 1979 Nov;72(11):1396-8.

PMID:
505071

Supplemental Content

Loading ...
Support Center